Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orthofix MedicalFRA:OM2 +1.75%60 Buyback Yield % is -1.35 as of Aug. 21, 2026. GuruFocus rates FRA:OM2 with a GF Score™ of 60/100 and a GF Value™ of €12.11 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 334 Medical Devices & Instruments companies, Orthofix Medical ranks worse than 54.79% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Orthofix Medical's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OM2 vs VMD, VREX, KIDS: Buyback Yield % Comparison
For the Medical Devices subindustry, Orthofix Medical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orthofix Medical Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Orthofix Medical's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Orthofix Medical's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orthofix Medical (FRA:OM2) has a Buyback Yield % of -1.35 as of Aug. 21, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Orthofix Medical and its competitors. According to the industry distribution chart, Orthofix Medical ranks #183 out of 334 companies in the Medical Devices & Instruments industry, placing it in the top 54.8%.
Is Orthofix Medical's Buyback Yield % too high?
Orthofix Medical's current Buyback Yield % is -1.35. Based on the distribution chart, Orthofix Medical ranks #183 out of 334 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Orthofix Medical has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orthofix Medical's Buyback Yield % compare to VMD and VREX?
According to the Medical Devices & Instruments industry distribution chart, Orthofix Medical ranks #183 out of 334 companies for Buyback Yield %. This places Orthofix Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Orthofix Medical and its competitors. Orthofix Medical's current Buyback Yield % is -1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orthofix Medical stock overvalued right now?
Based on GuruFocus' analysis, Orthofix Medical (FRA:OM2) is currently considered Modestly Undervalued. The stock's GF Value™ is €12.11, compared to a current price of €8.70 — trading 28.2% below its estimated fair value. The current Buyback Yield % is -1.35. Orthofix Medical's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Orthofix Medical (FRA:OM2), the current Buyback Yield % is -1.35 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orthofix Medical (FRA:OM2) Overvalued in 2026?
Based on GuruFocus' analysis, Orthofix Medical stock appears to be undervalued.
The current stock price of €8.70 is trading 28.2% below its estimated GF Value™ of €12.11.
GuruFocus considers Orthofix Medical to be Modestly Undervalued.
Key valuation signals for FRA:OM2:
Buyback Yield %: -1.35
GF Value™: €12.11 vs. price of €8.70 (28.2% below fair value)
No single metric tells the full story. See the FRA:OM2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
60GF Score
Get the complete analysis for FRA:OM2
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OM2 has been successfully added to your 
